Key terms
About AKBA
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AKBA news
Mar 31
6:30am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 28
12:08pm ET
Akebia price target raised to $6 from $5 at H.C. Wainwright
Mar 28
8:46am ET
Largest borrow rate increases among liquid names
Mar 28
7:00am ET
Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Akebia Therapeutics (AKBA) and Moderna (MRNA)
Mar 28
6:23am ET
Akebia Therapeutics Celebrates FDA Approval of Anemia Drug
Mar 27
9:09pm ET
Akebia gets FDA approval of Vafseo for treatment of Aenmi due to CKD
Mar 20
11:06am ET
Biotech Alert: Searches spiking for these stocks today
Mar 18
11:03am ET
Biotech Alert: Searches spiking for these stocks today
Mar 16
12:30pm ET
Analysts’ Top Healthcare Picks: Verastem (VSTM), Akebia Therapeutics (AKBA)
Mar 16
2:00am ET
Akebia Therapeutics Confronts Financial Reporting Flaw: Inventory Management Weakness Sparks Investor Concern
Mar 15
4:23pm ET
Akebia Therapeutics Announces CFO Transition and Interim Plan
Mar 14
4:18pm ET
Akebia reports Q4 EPS 0c, consensus (4c)
Feb 13
8:13am ET
Akebia Therapeutics Extends COO and SVP Tenures for Stability
Jan 31
10:56am ET
Biotech Alert: Searches spiking for these stocks today
Jan 31
10:35am ET
Optimistic Buy Rating for Akebia Therapeutics Amid Strategic Financial Restructuring and Anticipated FDA Approval
Jan 09
8:35am ET
Akebia names Nicholas Grund as Chief Commercial Officer
Jan 07
5:28am ET
BTIG Remains a Buy on Akebia Therapeutics (AKBA)
Jan 02
9:10am ET
BTIG Keeps Their Buy Rating on Akebia Therapeutics (AKBA)
No recent press releases are available for AKBA
AKBA Financials
Key terms
Ad Feedback
AKBA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AKBA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
